A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)
A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)
Active, not recruiting · NCT05347225 · Registry updated 2026-04-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005) | Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Active, not recruiting | Phase 1 | 2026-04-30 | NCT05347225 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Merck Sharp & Dohme LLC | 650 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Guangdong Provincial People's Hospital-hematology department ( Site 1002) | Guangzhou | China | 1 |
| Henan Cancer Hospital-hematology department ( Site 1003) | Zhengzhou | China | 1 |
| Hunan Cancer Hospital ( Site 1004) | Changsha | China | 1 |
| Institute of hematology&blood disease hospital-Hematology ( Site 1001) | Tianjin | China | 1 |
| SUN YAT-SEN UNIVERSITY CANCER CENTRE-Internal medicine ( Site 1007) | Guangzhou | China | 1 |